NeoGenomics, Inc. (NASDAQ:NEO) Receives $13.83 Average PT from Analysts

NeoGenomics, Inc. (NASDAQ:NEO) has earned an average recommendation of “Hold” from the eleven analysts that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $13.83.

Several equities analysts have commented on NEO shares. Bank of America decreased their price objective on shares of NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a report on Wednesday, February 19th. Leerink Partnrs downgraded shares of NeoGenomics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 30th. Needham & Company LLC decreased their price objective on shares of NeoGenomics from $18.00 to $8.50 and set a “buy” rating on the stock in a report on Tuesday, April 29th. The Goldman Sachs Group decreased their price objective on shares of NeoGenomics from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, April 30th. Finally, Piper Sandler set a $12.00 price target on shares of NeoGenomics and gave the company an “overweight” rating in a research note on Tuesday, May 6th.

NeoGenomics Price Performance

Shares of NASDAQ NEO opened at $7.42 on Friday. The business’s 50 day moving average price is $8.65 and its two-hundred day moving average price is $12.51. The company has a market cap of $954.92 million, a PE ratio of -11.97 and a beta of 1.60. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. NeoGenomics has a twelve month low of $6.08 and a twelve month high of $19.12.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, April 29th. The medical research company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.06). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The company had revenue of $168.04 million during the quarter, compared to analyst estimates of $171.38 million. During the same quarter in the prior year, the firm earned ($0.02) earnings per share. NeoGenomics’s revenue for the quarter was up 7.6% on a year-over-year basis. On average, analysts predict that NeoGenomics will post -0.2 EPS for the current year.

Insider Transactions at NeoGenomics

In other NeoGenomics news, Director Michael Aaron Kelly acquired 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 27th. The stock was acquired at an average price of $7.60 per share, for a total transaction of $38,000.00. Following the acquisition, the director now directly owns 5,000 shares in the company, valued at $38,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Warren Stone bought 5,700 shares of the firm’s stock in a transaction on Monday, May 12th. The shares were purchased at an average cost of $8.58 per share, with a total value of $48,906.00. Following the transaction, the chief operating officer now directly owns 108,280 shares in the company, valued at approximately $929,042.40. This trade represents a 5.56% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 70,600 shares of company stock valued at $550,438. 2.40% of the stock is currently owned by insiders.

Institutional Trading of NeoGenomics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NEO. SBI Securities Co. Ltd. acquired a new stake in shares of NeoGenomics during the 4th quarter worth approximately $26,000. Brooklyn Investment Group acquired a new stake in shares of NeoGenomics during the 1st quarter worth approximately $35,000. CWM LLC grew its position in shares of NeoGenomics by 42.6% during the 1st quarter. CWM LLC now owns 6,299 shares of the medical research company’s stock worth $60,000 after buying an additional 1,883 shares during the period. AlphaQuest LLC acquired a new stake in shares of NeoGenomics during the 1st quarter worth approximately $60,000. Finally, Sterling Capital Management LLC grew its position in shares of NeoGenomics by 788.7% during the 4th quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company’s stock worth $61,000 after buying an additional 3,289 shares during the period. Institutional investors and hedge funds own 98.50% of the company’s stock.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.